Omega-3 (EPA/DHA)
Marine PUFAs: SPMs ↓ inflammation/cachexia, ↑ chemo tolerance; strong trial support in lung/colorectal/pancreatic/breast.
Forms: Molecularly distilled softgels (1-2 g EPA+DHA per serving) · Liquid triglyceride form for high-dose
Key Takeaway
Marine omega-3s generate specialized pro-resolving mediators (SPMs) that quell inflammation, help preserve weight/lean mass, and can improve treatment tolerance and select outcomes in cancer cachexia.
Evidence at a glance
20+ RCTs/meta; cachexia WMD +1-2 kg lean mass; inflammation CRP SMD -0.4; chemo adherence ↑15-20%; strongest in GI/lung; ongoing in immunotherapy combos.
How it may work
EPA/DHA incorporate into membranes, shifting eicosanoid profiles away from arachidonic acid derivatives and spawning resolvins/protectins/maresins. This reduces NF-κB/COX-2 signaling and cytokines (IL-6/TNF). In cachexia, omega-3s help stabilize weight and lean mass, temper anorexia/inflammation, and may enhance chemo efficacy via membrane fluidity and lipid raft effects.
Targets & pathways
Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.
Often studied / combined with
Combinations reported in the literature, not a protocol or a recommendation.
- Cisplatin: Reduced nephrotoxicity and better tolerance in lung trials.
- Curcumin: Amplified anti-inflammatory SPM synergy in colorectal.
- Resveratrol: Cooperative cachexia reversal in pancreatic models.
- Quercetin: Enhanced resolution mediators in breast cancer.
Overlapping mechanisms
- Inflammation ↓: Overlaps with NSAIDs/SPMs; monitor omega-6:3 ratio.
- Cachexia: Redundant with megestrol; combine with resistance training.
Safety & interactions
Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.
- anticoagulantsMonitorModerateTheoreticalAdditive antiplatelet effects.
- chemotherapySynergizeLowTheoreticalMay enhance efficacy via membrane changes.
- CisplatinSynergizeLowTheoreticalImproved tolerance in lung cancer trials.
Timing
- With-meal: Enhances absorption and reduces reflux.
- BID: Divided for steady blood levels.
References
- PMC10538050: Omega-3 in cancer cachexia meta-analysis
- DOI 10.1016/j.canlet.2021.05.026: SPM mechanisms in inflammation
- DOI 10.3389/fnut.2022.797513: Chemo tolerance review
- DOI 10.1016/j.nut.2024.112413: Omega-3 and QoL in advanced cancer
- DOI 10.3390/nu13082654: Synergy with cisplatin in lung models
- PMC10221542: Combination with curcumin in colorectal cancer
Research
No published studies for Omega-3 (EPA/DHA) yet
New studies appear here once they’ve been reviewed. Browse all studies.
Dose: as studied, not a recommendation
Ranges seen in adjunct / practice use: 1–4 g EPA+DHA/day (po) divided with meals; triglyceride form preferred, Cachexia trials 2-3 g/day; up to 4 g for inflammation; check omega-3 index for personalization; avoid oxidized products..
Trials studying Omega-3 (EPA/DHA)
Loading current trials from ClinicalTrials.gov… Search ClinicalTrials.gov →
Appears in these protocol claims
Omega-3 (EPA/DHA) is named in these protocols discussed online. Listed for transparency: being part of a protocol is not evidence that it works, and OncoForge does not endorse them.
- Joe Tippens / Fenbendazole Protocol : Fenbendazole-centered supplement stack popularized through a remission story and online groups.
- Jane McLelland / Metabolic Blocking Claims : Multi-pathway metabolic strategy based around starving cancer fuel routes and blocking escape pathways.
- Gerson, Gonzalez, Budwig, RSO, IPT, and Other Long-Running Claims : Older alternative or clinic-based approaches with strong testimonial communities and major evidence disputes.